Skip to content
Parakho

Glenmark Pharmaceuticals Ltd

NSE GLENMARKBSE 532296glenmarkpharma.com

Q1 FY27, unaudited

Revenue
₹2,434.99 Cr
Profit after tax
₹735.64 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year ago6M FY26
Revenue from operations2,434.99+1.67%2,146.58
Other income115.41+66.45%307.88
Total income2,550.40+3.50%2,454.45
Employee benefit expense454.08+11.17%461.35
Finance costs23.25+50.38%17.91
Depreciation & amortisation62.32+8.12%60.13
Total expenses1,907.30+9.62%2,193.09
Profit before tax866.10+115.90%-107.40
Tax expense130.47+83.91%-33.50
Profit after tax735.64+122.77%-73.90
Total comprehensive income736.24+123.31%-77.65
Earnings per share
Earnings per share, basic₹26.07₹-2.62
Earnings per share, diluted₹26.06₹-2.62

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

6M FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

A transcript for the Q1 FY27 call was filed with the exchange; Parakho has not summarised it yet.

All quarters

Filings

12 shown · 62 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 06 Oct 2026.